- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
T½: in neonates (when administered to the mother), the elimination half-life is extended to about 29 hours; in children up to 1 year of age, the elimination half-life is 11-12 hours; in children of 1 to 12 years, the elimination half-life is 8 hours. The therapeutic plasma concentration is 0.2-1 mg/l.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| Supraventricular arrhythmias, life-threatening ventricular arrhythmias |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
The dose should be adjusted in patients with renal function disorders. There are no instructions available stating how the dose should be adjusted.
Clinical consequences
Plasma concentrations above 0.7–1.0 mg/l are associated with an increased risk of side effects occurring.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Hypotension, tingling fingers, vision problems, hair loss, extension of the QTc interval. Pro-arrhythmic effects in particular in patients with structural heart disease and/or poor left ventricular function. Bradycardia, broader QRS complex, negative inotropic effect, nausea, vomiting, perioral paraesthesia, ECG changes, loss of consciousness after effort (probably due to ventricular tachycardia). Sleepiness, psychiatric problems. Abnormal ECG and tremor have been seen at high doses.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications in children
Extended QTc interval, asymptomatic and non-serious symptomatic ventricular arrhythmia, myocardial infarction in the previous history (unless the arrhythmia is life-threatening).
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Treatment with flecainide should be adjusted in a clinical setting and dose adjustments must be implemented in the clinic, with ECG and plasma concentration monitoring.
Milk and dairy products can reduce the resorption of flecainide; administering flecainide half an hour before food or 2 hours after food is preferable. If this is not practically possible, it is recommended that flecainide should always be given at the same moment with respect to the nutrition so that the effect of any interaction is not a variable that affects the level.
Caution is needed when changing the feeding pattern in a way that lowers the intake of milk and dairy products (as this can elevate the plasma concentration of flecainide).
The dose should be adjusted in patients with hepatic or renal function disorders. Plasma concentrations above 0.7–1.0 mg/l are associated with an increased risk of side effects occurring.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Antiarrhythmics, class Ia | ||
|---|---|---|
| C01BA02 | ||
| C01BA01 | ||
| Antiarrhythmics, class Ic | ||
|---|---|---|
| C01BC03 | ||
| Antiarrhythmics, class III | ||
|---|---|---|
| C01BD01 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- Fish FA, et al., Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group, J Am Coll Cardiol, 1991, 18, 356-65
- Musto B, et al., Flecainide single oral dose for management of paroxysmal supraventricular tachycardia in children and young adults., Am Heart J, 1992, 124, 110-5
- Perry JC, et al., Flecainide acetate for treatment of tachyarrhythmias in children: review of world literature on efficacy, safety, and dosing., Am Heart J, 1992, 124, 1614-21
- Perry JC, et al., Flecainide acetate for resistant arrhythmias in the young: efficacy and pharmacokinetics., J Am Coll Cardiol, 1989, 14, 185-91
- Russell GA, et al., Flecainide toxicity., Arch Dis Child, 1989, 64, 860-2
- Schneeweiss A., New antiarrhythmic drugs. II.Flecainide, Pediatr Cardiol, 1990, 11, 143-6
- Zeigler V, et al, Flecainide for supraventricular and ventricular arrhythmias in children and young adults., Am J Cardiol, 1988, 62, 818-20
- KNMP Kennisbank, Handboek oralia VGTM, Geraadpleegd 29 dec 2014
- EMA, Artikel 45 procedure Flecainide, http://www.hma.eu/269.html, Geraadpleegd 21 mei 2014
- Chorin, E., et al., Long-term flecainide therapy in type 3 long QT syndrome., Europace, 2018, 20 (2), 370-376
- Liberman, L., et al., Usefulness of High-Dose Oral Flecainide for Termination of Recent-Onset Atrial Fibrillation in Children., Am J Cardiol, 2018, 121 (12), 1530-1533
- Ferlini M, et al, Flecainide as first-line treatment for supraventricular tachycardia in newborns., J Cardiovasc Med (Hagerstown), 2009, May;10(5), 372-5
- Viatris AS, SmPC Tambocor (MT-nr. 7126) 11.07.2023, www.legemiddelsok.no
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
